Simeprevir for the treatment of hepatitis C virus infection

Simeprevir (TMC435, Olysio™), a second-generation hepatitis C virus (HCV) protease inhibitor, has been recently approved for the treatment of genotype 1 chronic hepatitis C in combination with pegylated interferon and ribavirin. This molecule has very different characteristics from first-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Izquierdo, Laure, Helle, François, François, Catherine, Castelain, Sandrine, Duverlie, Gilles, Brochot, Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157399/
https://www.ncbi.nlm.nih.gov/pubmed/25206310
http://dx.doi.org/10.2147/PGPM.S52715

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4157399/
https://www.ncbi.nlm.nih.gov/pubmed/25206310
http://dx.doi.org/10.2147/PGPM.S52715

Ejemplares similares